RxDoctor Payments Data

Robert McCray, MD

Cardiovascular Disease · Chesapeake, VANPI 1477653236

Payments from drug & device makers

$1,985in general payments, 2019–2025

Across 122 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$503
  • Amgen$218
  • Scpharmaceuticals Inc.$205
  • Astellas Pharma US Inc$136
  • Sanofi-aventis U.S. LLC$129
  • Pfizer$115
  • plus $680 from 17 others

What the payments were for

  • Food & beverage$1,985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,985 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$328,710
Medicare patients
1,541
Services billed
4,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$220,737
EntrestoSacubitril/Valsartan70$99,048
XareltoRivaroxaban67$65,483
Repatha SureclickEvolocumab40$31,987
JardianceEmpagliflozin17$30,145
BrilintaTicagrelor14$10,037
Flecainide Acetate51$3,196
Ranolazine ErRanolazine41$2,300
Metoprolol Succinate184$2,243
Carvedilol122$1,167
Ezetimibe38$882
Amlodipine Besylate165$824
Warfarin Sodium82$823
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$802
Rosuvastatin Calcium46$799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$220,737199 claims
NovartisEntresto$503$99,04870 claims
Johnson & JohnsonXarelto$81$65,48367 claims
Boehringer IngelheimJardiance$35$30,14517 claims
AstraZenecaBrilinta$72$10,03714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →